

FINAL TERMS

MIFID II PRODUCT GOVERNANCE – Solely for the purposes of the manufacturer’s product approval process, the target market assessment in respect of the Products has led to the conclusion that: (i) the target market for the Products is eligible counterparties, professional clients and retail clients, each as defined in Directive 2014/65/EU, as amended (**MiFID II**); and (ii) all channels for distribution of the Products to eligible counterparties and professional clients are appropriate; and (iii) the following channels for distribution of the Products to retail clients are appropriate – investment advice, portfolio management, non-advised sales and pure execution services, subject to the distributor’s suitability and appropriateness obligations under MiFID II, as applicable. Any person subsequently offering, selling or recommending the Products (a **distributor**) should take into consideration the manufacturer’s target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Products (by either adopting or refining the manufacturer’s target market assessment) and determining appropriate distribution channels, subject to the distributor’s suitability and appropriateness obligations under MiFID II, as applicable. For the avoidance of doubt, the Issuer is not a manufacturer or distributor for the purposes of MiFID II.

FINAL TERMS DATED 25 March 2026

21Shares AG

(incorporated in Switzerland)

LEI: 254900UWHMJRRODS3Z64

Issue of
65,000 Products (the **Products**)

(Issue up to 21.000.000.000 Products specifically for the purpose of the admission and introduction to trading on the regulated Market of Frankfurt Stock Exchange)

pursuant to the Issuer’s
Exchange Traded Products Programme

This document constitutes the Final Terms of the Products described herein.

PART A - CONTRACTUAL TERMS

The Base Prospectus referred to below (as completed by these Final Terms) has been prepared on the basis that, except as provided in sub-paragraph (ii) below, any offer of Products in any Member State of the EEA which has implemented the Prospectus Regulation (each, a **Relevant Member State**) will be made pursuant to an exemption under the Prospectus Regulation, as implemented in that Relevant Member state, from the requirement to publish a prospectus for offers of the Products. Accordingly any person making or intending to make an offer of the Products may only do so:

- (i) in circumstances in which no obligation arises for the Issuer to publish a prospectus pursuant to Article 1(4) of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation, in each case, in relation to such offer; or
- (ii) in those Non-Exempt Offer Jurisdictions mentioned in the following paragraph, provided such person is one of the persons mentioned in the following paragraph and that such offer is made during the Offer Period specified for such purpose therein.

An offer of the Products may be made by the Issuer or by the Authorised Offerors specified in Part B of these Final Terms other than pursuant to Article 1(4) of the Prospectus Regulation in Austria, Belgium, Bulgaria, Croatia, Czech Republic, Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden (**Non-Exempt Offer Jurisdictions**) from the Issue Date of the Bonds (inclusive) to the later of (i) the date of expiry of the Base Prospectus and (ii) the expiry of the validity of a new Base Prospectus succeeding the Base Prospectus (the **Offer Period**).

Neither the Issuer nor any Authorised Participant has authorised, nor do they authorise, the making of any offer of Products in any other circumstances.

Terms used herein shall be deemed to be defined as such for the purposes of the relevant General Terms and Conditions of the Products indicated in the table below (the **Conditions**) issued by 21Shares AG (the **Issuer**) set forth in the Base Prospectus dated 20 February 2026, including any Supplements thereto (the **Base Prospectus**), which constitutes a base prospectus for purposes of Regulation (EU) 2017/1129, as amended (the **Prospectus Regulation**). This document constitutes the Final Terms of the Products described herein for the purposes of Article 8(5) of the Prospectus Regulation and must be read in conjunction with the Base Prospectus (and any supplement thereto). Full information on the Issuer and the offer of the Products is only available on the basis of the combination of these Final Terms and the Base Prospectus. The Base Prospectus (together with any supplement thereto) is available for viewing at the registered office of the Issuer and on the website of the Issuer (<https://21shares.com/ir#prospectus>) by selecting Base Prospectus. The Final Terms will be available for viewing at the registered office of the Issuer and on the website of the Issuer (<https://21shares.com/ir#final-terms>) by selecting Base Prospectus and then Final Terms and the respective Security Code.

The Base Prospectus, together with the Final Terms, constitutes the prospectus with respect to the Products described herein.

(i) Issue Date	03 December 2025		
(ii) Series	21shares Morpho ETP (MORPH)		
(iii) Tranche	1		
(iv) Date on which Products become fungible	Not Applicable		
(v) Aggregate Number of Products represented by this Tranche	65,000		
(vi) Issue Price	The initial Crypto Asset Collateral, Equity Asset Collateral and/or Commodity Asset Collateral as per 02 December 2025 17:00 CET/CEST, is composed of the following Crypto Assets, Equity Assets and/or Commodity Assets per Product:		
	Collateral Name	Amount per Product	Weighting
	Morpho (MORPHO)	13.67053999	100%

	<i>The Issue Price is subject to any applicable fees and commissions of the person offering the Product.</i>
(vii) General Terms and Conditions applicable to the Products	General Terms and Conditions for Products related to Crypto Assets and/or Commodity Assets
Underlying	<p>Morpho (MORPHO)</p> <p>The Issuer may either hold the native token or the network token of the underlying.</p> <p>Relevant Underlying Exchange: according to the methodology by Kaiko Indices</p> <p>Relevant Currency: USD or USD equivalents</p> <p>Information regarding past performance, further performance and volatility of the Underlying is available, free of charge, at www.kaiko.com.</p>
Basket	Not Applicable
Index	Kaiko MORPHO Reference_Rate LDN - (KK_RFR_MORPHOUSD_LDNLF)
Underlying Component	Not Applicable
Redemption Amount	<p>The Redemption amount is calculated as follows:</p> $\text{Redemption Amount} = \sum_{i=1}^n p_i * q_i - rf$ <p><i>Where (for each Crypto Asset Collateral and Commodity Asset Collateral] (i)):</i></p> <p><i>n = number of underlyings,</i></p> <p><i>p_i = price of asset sold (USD),</i></p> <p><i>q_i = quantity sold, reflecting any investor fees,</i></p> <p><i>rf = redemption fee equal to \$150 plus 4 bps of redemption amount per redemption order</i></p> <p>The Redemption Amount may also be subject to additional fees related to the transfer of fiat assets.</p> <p>In the case of the Redemption Amount per Product as calculated in accordance with the formula set out above being less than the smallest denomination of the Settlement Currency (i.e., U.S.\$0.01, €0.01, CHF 0.01, £0.01 or the equivalent in other Settlement Currencies), the Redemption Amount per Product shall be deemed to be, and will be, reduced to zero.</p> <p>Redemptions by Authorised Participants pursuant to Condition 5.3 (<i>Redemption at the Option of an Authorised Participant</i>) shall be settled on an in-kind basis unless the Issuer permits such redemption to be settled in accordance with Condition</p>

	5.5 (<i>Cash Settlement</i>). The calculation of the Redemption Amount may fluctuate as a result of tracking errors relating to the Underlyings, as described in the section headed " <i>Risk Factors</i> " set out in the Base Prospectus.
Amount of any expenses and taxes specifically charged to the subscriber or purchaser:	Investor fee of 2.50% of the aggregate value of the Crypto Asset Collateral annually. Fee will be calculated on a daily basis at 17:00 CET/CEST. Fees related to the Product will be collected in-kind. The Issuer reserves the right to, in its absolute discretion and from time to time, reduce the otherwise applicable Investor Fee to a lower fee or even to zero, in each case on a temporary basis subject to reinstatement of a higher Investor Fee (capped at the maximum level of the original Investor Fee).
Long Exposure	Normal Exposure
Distribution	Not applicable Unless, and where applicable only to the extent, the Issuer has agreed to share any net earned staking rewards pursuant to the above, no such earned staking rewards will be shared with Investors in any manner.
Investor Put Date	04 December in each year, beginning on 04 December 2026
Final Fixing Date	As specified in any termination notice
Product Calculation Agent	Name: NAV Consulting Inc. Address: 8220 Lincoln Avenue, Skokie, IL 60077, USA
Calculation Agent:	Name: NAV Consulting Inc. Address: 8220 Lincoln Avenue, Skokie, IL 60077, USA
Administrator:	Name: NAV Consulting Inc. Description: NAV is a privately owned fund administrator recognized for its comprehensive, cost-effective fund administration solutions for funds across the globe, including hedge funds, private equity funds, and digital assets funds.
Swiss Paying Agent	ISP Securities AG, Bellerivestrasse 45, 8008 Zurich, Switzerland
Additional Paying Agent	Global Paying Agent: Bank Frick & Co Aktiengesellschaft
Cash Settlement	Applicable, other than as set out in Condition 5.3 (Redemption of Products at the Option of an Authorised Participant)
Settlement Currency	USD
Exchange	Euronext Paris and Amsterdam
Exchange Business Day	As indicated in General Terms and Conditions

Market Maker	Flow Traders B.V., Jacob Bontiusplaats 9, 1018LL Amsterdam, The Netherlands
Authorised Participant	a) Flow Traders B.V., Jacob Bontiusplaats 9, 1018LL Amsterdam, The Netherlands; b) Jane Street Financial Limited, Floor 30, 20 Fenchurch Street, London EC3M 3BY, United Kingdom c) and each Authorised Participant mentioned on the Issuer's website (https://21shares.com/ir/aps/)
Custodian	The Issuer may use any of the below Custodians for the Product: Coinbase Custody Trust Company LLC Coinbase Custody International Ltd Copper Markets (Switzerland) AG Zodia Custody Limited Anchorage Digital Bank N.A. BitGo Bank and Trust NA.
Staking Provider	Not Applicable
Minimum Investment Amount	1 Product
Minimum Trading Lot	Applicable, 1 Product
Representative	
(viii) Responsibility	The Issuer accepts responsibility for the information contained in these Final Terms.
(ix) Third Party Information	Not applicable
(x) Date of Board of Directors approval of issuance	14 November 2025

PART B - OTHER INFORMATION

(xi) Listing and admission to trading	<p>Application has been made for the Products to which these Final Terms apply to be admitted to Euronext Paris and Amsterdam. The first trading date is expected to be 03 December 2025.</p> <p>Application has been made for the Products to which these Final Terms apply to be admitted to Borsa Italiana. The first trading date is expected to be 09 February 2026.</p>
(xii) Notification	<p>The <i>Finansinspektionen</i> (the SFSA) of Sweden has provided the competent authorities of Austria, Belgium, Bulgaria, Croatia, Czech Republic, Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, and Spain with a certificate of approval attesting that the Base Prospectus has been drawn up in accordance with the Prospectus Regulation.</p>
(xiii) Interests of natural and legal persons involved in the issue	<p>So far as the Issuer is aware, no person involved in the offer of the Products has an interest material to the offer</p>
(xiv) Additional Considerations	<p>Not Applicable</p>
(xv) ECB eligibility	<p>The Product is expected to be ECB eligible</p>
(xvi) Distribution	<p>An offer of the Products may be made by the Authorised Offerors other than pursuant to Article 1(4) of the Prospectus Regulation in Austria, Belgium, Bulgaria, Croatia, Czech Republic, Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden (Non-Exempt Offer Jurisdictions) during the Offer Period. See further "Terms and Conditions of the Offer" below.</p>
(xvii) Additional Selling Restrictions	<p>Not Applicable</p>
ISIN and other Security Codes	<p>ISIN: CH1506167027</p> <p>Valor: 150616702</p> <p>WKN: A4AQT2</p>
Names and Addresses of Clearing Systems	<p>SIX SIS AG, Baslerstrasse 100, P.O. Box, 4600 Olten, Switzerland</p>
(xviii) Reasons for the offer:	<p>As stated in the Base Prospectus.</p>
(xix) Estimated total	<p>Not Applicable</p>

expenses of the issue/offer and the estimated net amount of the proceeds:	
(xx) Date of authorisation:	13 November 2018, as complemented by the date of board of directors approval of issuance
(xxi) Terms and Conditions of the Offer	Products are made available by the Issuer for subscription only to Authorised Participants
(xxii) Offer Price:	Not Applicable. An Investor intending to acquire or acquiring any Products from an Authorised Offeror will do so, and offers and sales of the Products to such Investor by an Authorised Offeror will be made, in accordance with any terms and other arrangements in place between that Authorised Offeror and such Investor including as to price, allocations and settlement arrangements.
(xxiii) Conditions to which the offer is subject:	Offers of the Products are conditional upon their issue and, as between the Authorised Offeror(s) and their customers, any further conditions as may be agreed between them.
(xxiv) Description of the application process:	Not Applicable
(xxv) Description of the possibility to reduce subscriptions and manner for refunding excess amount paid by applicants	Not Applicable
(xxvi) Details of the minimum and/or maximum amount of application	Not Applicable
(xxvii) Details of the method and time limited for paying up and delivery of the Products	Not Applicable
(xxviii) Manner in and date on which results of the offer are made available to the public	Not Applicable

<p>(xxix) Procedure for exercise of any right of pre-emption, negotiability of subscription rights and treatment of subscription rights not exercised</p>	<p>Not Applicable</p>
<p>(xxx) Whether tranche(s) have been reserved for certain countries</p>	<p>Not Applicable</p>
<p>(xxxii) Process for notification to applicants of the amount allotted and the indication whether dealing may begin before notification is made</p>	<p>Not Applicable</p>
<p>(xxxiii) Name(s) and address(es), to the extent known to the Issuer, of the places in the various countries where the offer takes place</p>	<p>Not Applicable</p>
<p>(xxxiii) Name and address of financial intermediary/ies authorised to use the Base Prospectus, as completed by these Final Terms (the Authorised Offerors)</p>	<p>a) Flow Traders B.V., Jacob Bontiusplaats 9, 1018LL Amsterdam, The Netherlands; b) Jane Street Financial Limited, Floor 30, 20 Fenchurch Street, London EC3M 3BY, United Kingdom; and c) each Authorised Participant expressly named as an Authorised Offeror on the Issuer's website (https://21shares.com/ir/aps/).</p>